IGC Pharma, Inc. (IGC) stock

IGCNYSEPharmaceutical PreparationsFiscal year ends December 31

Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 2/309% above fair value

$0.18−0.01 (-4.61%)

Close on Nov 13, 2026Market cap $18.20MP/E –Yield –

IGC Pharma EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

IGC Pharma has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is IGC.

Revenue growth-15.4% · median -18.9%

Gross margin21.9% · median 59.8%

Operating margin-986.8% · median -3360.5%

Net margin-702.1% · median -2446.5%

Advertisement
300 × 250

See a number that looks wrong?